TMCnet News
Alnylam Appoints Pushkal Garg, M.D., Senior Vice President, Clinical Development [Global Data Point](Global Data Point Via Acquire Media NewsEdge) At Alnylam, he will join the existing development team and be responsible for managing the company's clinical research, clinical operations, and biometrics functions. We are entering a particularly exciting time in the evolution of our company where clinical data from our pipeline of novel RNAi therapeutics highlight what we believe to be significant potential for RNAi therapeutics as a new class of genetic medicines. Accordingly, we are delighted to welcome Pushkal to the Alnylam team. His experience and expertise in early and late-stage drug development will be tremendously valuable as we continue to advance our pipeline of RNAi therapeutics through the clinic," said Akshay Vaishnaw, M.D., Ph.D., Executive Vice President and Chief Medical Officer of Alnylam. "Indeed, Pushkal brings a deep understanding of the biotechnology and pharmaceutical industries, extensive experience, as well as a proven track record of success, and I am excited to have him join our team as we expand our clinical development capabilities." "The breakthrough field of RNAi therapeutics represents a unique opportunity to develop and bring to market novel drugs that have the potential to treat a broad array of human diseases with significant unmet need. Alnylam has made tremendous progress in advancing this innovative technology towards an entirely new class of medicines," said Pushkal Garg, M.D., Senior Vice President, Clinical Development at Alnylam. "I am thrilled to be joining Akshay and the broader Alnylam development team at this important stage, as we advance our pipeline of novel therapies through the clinic. I look forward to being part of a team that is so passionate and committed to advancing RNAi therapeutics to patients." Dr. Garg joins Alnylam with close to 15 years of experience in clinical drug development. Most recently, he served as Vice President, Global Clinical Research, Immunoscience at Bristol-Myers Squibb (BMS). In this role he was responsible for strategic leadership of the Immunoscience franchise and the successful development of multiple clinical assets across immune-mediated diseases in the areas of rheumatology, gastroenterology, nephrology, and transplantation. During his eight-year tenure at BMS, he was instrumental to the late-stage development and approval of Nulojix (belatacept) for kidney transplant recipients, and for supplementary biologics license applications (BLA) for Orencia (abatacept) around the world. Previously, Dr. Garg was at Millennium Pharmaceuticals, where he worked in various roles of increasing responsibility, overseeing the clinical development of multiple small molecule and biologic therapeutics for the treatment of inflammatory disorders. Dr. Garg received a Bachelor of Arts with high honors in Biochemistry from the University of California, Berkeley, and an M.D. from the University of California, San Francisco. He completed residency training in Internal Medicine at UCSF, was a fellow in the Robert Wood Johnson Clinical Scholars Program at Johns Hopkins University, and served on the faculty of Harvard Medical School and the Brigham %7E Women's Hospital in Boston prior to joining industry. (c) 2014 GlobalData Provided by SyndiGate Media Inc. (Syndigate.info). |